Opiant Pharmaceuticals — Merger or Acquisition (November 2022)
17 slides from Opiant Pharmaceuticals's merger presentation, Nov 15, 2022
Slide 1: Indivior To Acquire Opiant Pharmaceuticals
Indivior To Acquire Opiant Pharmaceuticals Acquisition Strengthens and Extends Indivior’s Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to Confront Illicit Synthetic Opioids Like
Slide 2: Indivior
se SVE INDIVIOR
Slide 3: Forward-looking statements
Forward-looking statements
Slide 4: ‘Remand om sin pk aha td eed
‘Remand om sin pk aha td eed Steen nr sas es nn ue wes ees eo moe oe Sop ce este ee yar yon mee SUSicseranane atc atteminne ache oy sana opse tases macros ace sab saan SLE ae rare ec py mena nga aenomor
Slide 5: Opiant Pharmaceuticals
piant Pharmaceuticals
Slide 6: Compelling strategic & financial rationale
Compelling strategic & financial rationale Sgn Fann aoe ae G ors ue al of 30m 200) Esrircieserr ena dial G “aaacon anetk © sms @ mazar
Slide 7: Leading addiction treatment and science platform upon closing
leading a ion treatment and science platform upon closing in na a sy
Slide 8: OPNT003 addresses the current wave of US opioid overdose driven by synthetics
OPNTOO3 addresses the current wave of US opioid overdose being driven by synthetics 12 Mtn oper on Nant tong omine Day ge Der Smut ite
Slide 9: Synthetic opioids are challenging current treatment options
Synthetic opioids are challenging current treatment options Most of the crews tetoanenas Cera ene 2° having to use perenne ae eee a BESO NVARCAN® (naloxone) per patient just t them breathing again”
Slide 10: Scientific evidence confirms OPNT003's potential to improve and sustain reversal of opioid overdose
Scientific evidence confirms OPNTO03’s potential to improve and sustain reversal of opioid overdose
Slide 11: Fast-Track designation expected 2022; expected approval Q3 2023
‘ast-Track” designation expected 04 2022; expected approval Q3 2023, o-¢ oo - eee ee slenomon
Slide 12: OPNT003 is complementary to SUBLOCADE and Patient Recovery
‘OPNTOO3 is complementary to SUBLOCADE® and Patient Recovery fom) (on es =) eg) qr ecrntntome etc (cn) NY enone
Slide 13: OPNT003 is complementary to SUBLOCADE and Patient Recovery
‘OPNTOO3 is complementary to SUBLOCADE® and Patient Recovery fom) (on es =) eg) qr ecrntntome etc (cn) NY enone
Slide 14: OPNT002 - Attractive opportunity as an as-needed nasal spray
OPNT0O2 — Attractive ‘opportunity with the potential to become “as needed” nasal spray when patient anticipates drinking or craving alcohol ‘Wnasman gsm chan ong enone
Slide 15: Transaction summary
Transaction summary* = ome SSUES args hore cerernrentnonenseaernememnyceame “Son ee nen ate a RO semontor .
Slide 16: Narcan Owner Opiant to Be Acquired by Indivior for $145 Million
Narcan Owner Opiant to Be Acquired by Indivior for $145 Million The combination of addiction-drug makers could tap into billions of dollars in settlement and federal funds aimed at expanding access to treatment MARK CROSSLEY WELCOMING VIDEO SCRIPT My name is Mark Crossley, and I’d like to personally
Slide 17: Indivior
vW NA AS INDIVIOR
Opiant Pharmaceuticals — Merger or Acquisition (November 2022) on 6ix